While the exact mechanisms of action of CLF are under investigation, we showed that CLF activates the peroxisome proliferator-activated receptor-gamma (PPAR-γ) and synergizes with tyrosine-kinase inhibitors in the treatment of CML [23]. Here, PPARG is linked to chronic myelogenous leukemia, BCR-ABL1 positive.